Compare · MGNX vs ZLAB
MGNX vs ZLAB
Side-by-side comparison of MacroGenics Inc. (MGNX) and Zai Lab Limited (ZLAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGNX and ZLAB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ZLAB is the larger of the two at $1.93B, about 7.2x MGNX ($267.0M).
- Over the past year, MGNX is up 181.6% and ZLAB is down 52.4% - MGNX leads by 234.0 points.
- MGNX has been more active in the news (18 items in the past 4 weeks vs 8 for ZLAB).
- MGNX has more recent analyst coverage (25 ratings vs 11 for ZLAB).
- Company
- MacroGenics Inc.
- Zai Lab Limited
- Price
- $4.21+4.21%
- $17.18+0.20%
- Market cap
- $267.0M
- $1.93B
- 1M return
- +31.56%
- -19.08%
- 1Y return
- +181.61%
- -52.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2013
- 2017
- News (4w)
- 18
- 8
- Recent ratings
- 25
- 11
MacroGenics Inc.
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Zai Lab Limited
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrödinger, Inc.; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.
Latest MGNX
- Director O'Brien Federica F. converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Jackson Scott Thomas converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Heiden William K converted options into 3,750 shares, increasing direct ownership by 3% to 114,750 units (SEC Form 4)
- Director Siegel Jay Philip converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Liu Margaret converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Chhabra Meenu converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- Director Hurwitz Edward converted options into 3,750 shares, increasing direct ownership by 9% to 47,824 units (SEC Form 4)
- Director Stump David C converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
- SEC Form 4 filed by Director Koenig Scott
- Director Ferrante Karen Jean converted options into 3,750 shares, increasing direct ownership by 34% to 14,750 units (SEC Form 4)
Latest ZLAB
- Chairperson & CEO Du Ying gifted 107,700 units of American Depositary Shares, decreasing direct ownership by 9% to 1,158,583 units (SEC Form 4)
- Zai Lab Announces Changes to Senior Leadership Team
- Zai Lab Limited filed SEC Form 8-K: Leadership Update
- Chairperson & CEO Du Ying exercised 261,092 units of American Depositary Shares at a strike of $1.74 and covered exercise/tax liability with 117,435 units of American Depositary Shares, increasing direct ownership by 13% to 1,266,283 units (SEC Form 4)
- Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $1,986,875 worth of American Depositary Shares (100,000 units at $19.87) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Legal Officer Edmondson Frazor Titus Iii sold $71,008 worth of American Depositary Shares (3,517 units at $20.19) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 19,849 units (SEC Form 4)
- Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $1.74 and sold $2,003,044 worth of American Depositary Shares (100,000 units at $20.03) as part of a pre-agreed trading plan (SEC Form 4)
- Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
- SEC Form 10-Q filed by Zai Lab Limited
- Zai Lab Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits